<DOC>
	<DOCNO>NCT02265939</DOCNO>
	<brief_summary>Patients require screen colonoscopy receive intraluminal spray NPO-13 per contraction region large bowel fifth time colonoscopy . The efficacy NPO-13 evaluate base proportion splay region contraction NPO-13 dosage ( primary outcome measure ) . The colonic spasm assess independent committee use record video image . The safety NPO-13 evaluate base adverse event adverse drug reaction ( ADRs ) observe administration seven day administration .</brief_summary>
	<brief_title>Phase â…¡ Dose Response Study NPO-13 Patients Undergoing Total Colonoscopy</brief_title>
	<detailed_description />
	<criteria>Inpatients outpatient either sex visit medical institution treatment followup confirm suspected colonic disease ( symptom ) meet criterion ( 1 ) ( 2 ) enrol study . Patients provide write informed consent voluntary participation study . 1 . Patients need colonoscopy 2 . Patients older 20 year time consent 1 . Patients history abdominal surgical treatment ( include laparoscopic surgery ) include gynecology operation 2 . Patients contraindication colonoscopy include paralytic ileus 3 . Patients history shock hypersensitivity lmenthol peppermint oil ( mint oil ) 4 . Patient contraindication bowel cleanse preparation 5 . Patients cancer treatment ( chemotherapy radiotherapy ) 6 . Patients need sedative colonoscopy 7 . Patients receive therapeutic colonoscopy 8 . Pregnant lactate woman , woman childbearing potential , woman plan become pregnant study 9 . Patients receive investigational drug within four month consent participate clinical study 10 . Patients expose NPO13 11 . Patients otherwise ineligible participation study investigator 's subinvestigator 's opinion</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
</DOC>